Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Cut by Redmile Group LLC

Redmile Group LLC reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,054,890 shares of the biopharmaceutical company’s stock after selling 1,191,702 shares during the period. Amicus Therapeutics accounts for about 4.6% of Redmile Group LLC’s investment portfolio, making the stock its 5th largest position. Redmile Group LLC owned about 2.36% of Amicus Therapeutics worth $66,457,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of FOLD. ProShare Advisors LLC raised its position in shares of Amicus Therapeutics by 32.6% in the 4th quarter. ProShare Advisors LLC now owns 96,787 shares of the biopharmaceutical company’s stock worth $912,000 after buying an additional 23,815 shares during the period. Prosight Management LP purchased a new position in shares of Amicus Therapeutics in the 4th quarter worth about $8,666,000. Parkman Healthcare Partners LLC lifted its stake in shares of Amicus Therapeutics by 29.6% in the 4th quarter. Parkman Healthcare Partners LLC now owns 784,376 shares of the biopharmaceutical company’s stock valued at $7,389,000 after purchasing an additional 179,058 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Amicus Therapeutics by 4.4% during the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company’s stock worth $35,866,000 after purchasing an additional 159,139 shares during the period. Finally, Orbimed Advisors LLC grew its holdings in shares of Amicus Therapeutics by 300.7% during the 4th quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company’s stock worth $21,528,000 after purchasing an additional 1,715,100 shares during the period.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $5.88 on Thursday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a 1 year low of $5.82 and a 1 year high of $12.65. The firm’s 50-day simple moving average is $7.47 and its 200-day simple moving average is $8.99. The firm has a market cap of $1.81 billion, a PE ratio of -32.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64.

Analyst Upgrades and Downgrades

FOLD has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group lowered their target price on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Friday, May 2nd. Finally, UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.